Amgen is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. Co.'s products include: Enbrel® (etanercept), which is used in indications for the treatment of adult patients with moderately to severely active rheumatoid arthritis, patients with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and patients with active psoriatic arthritis; and Prolia® (denosumab), which it is used for the treatment of postmenopausal women with osteoporosis at high risk of fracture or multiple risk factors for fracture; or in patients who have failed or are intolerant to other available osteoporosis therapy.
When researching a stock like Amgen, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from AMGN Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for AMGN stock — the real life supply and demand for the stock over time — and examines that data in different ways. |
38.70
Video: Technical Analysis